Disclaimer: All information on this section is of a general nature.
Before making any investment decision, you should consult your adviser.

Investment Ideas - BARD1 (BD1): a key step in the path to commercialisation

In August 2016, US-based Meso Scale Diagnostics (MSD) was engaged to transfer, optimise and validate BD1’s research-grade BARD1 Lung Cancer Test onto MSD’s commercial research-use only instrument platform. Note: MSD is a global leader in the development, manufacture, and commercialisation of assays and assay procedures.
8/02/2017 12:07:51 PM

Back to top